[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585957":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":27,"collaborators":26,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":26,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":26,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":26},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cabergoline 1 mg tab","ACTIVE_COMPARATOR","After the completion of the surgical procedure or medical induction for the early second-trimester abortion or fetal loss, the participant will be administered cabergoline 1mg orally with juice or water by the clinician or study investigator.",[13],"Drug: Cabergoline",{"label":15,"type":16,"description":17,"interventionNames":18},"Cabergoline 0.5 mg tab","EXPERIMENTAL","After the completion of the surgical procedure or medical induction for the early second-trimester abortion or fetal loss, the participant will be administered cabergoline 0.5mg orally with juice or water by the clinician or study investigator.",[13],[20],{"type":21,"name":22,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Cabergoline",[15,9],[25],"Dostinex",null,{"type":28,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100585957","phase-2-a-reduced-dose-of-cabergoline-for-lactation-inhibition-after-second-trimester-abortion-or-pregnancy-loss-100585957",false,"NCT06909123","A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss","LISTA3","Inclusion Criteria:\n\n* Pregnant people, ages 18 years or older\n* Intrauterine pregnancy between 16\u002F0-25\u002F6 weeks of gestation age (by ultrasound dating performed prior to or same day of enrollment visit)\n* Consented for an induced, elective abortion or undergoing management of fetal demise\n* English or Spanish speaking\n* Able to consent for a research study, literate in English or Spanish\n* Willing to comply with study procedures and follow-up\n* Access to smart phone throughout study\n\nExclusion Criteria:\n\n* Prior mastectomy (breast reduction or chest masculinization surgery acceptable)\n* Currently breastfeeding\n* Currently receiving dopamine agonist or antagonist therapy for other indication leg syndrome)\n* Contraindication to cabergoline (as per package insert)\n* Uncontrolled hypertension - defined as baseline BP \\> 160\u002F110, or chronic hypertension requiring more than one baseline medication, or current pregnancy-induced hypertension spectrum disorders (gestational hypertension, preeclampsia, eclampsia)\n* History of cardiac valvular disorders or valvular repair\n* History of pulmonary, pericardial, or retroperitoneal fibrotic disorders","FEMALE","18 Years","55 Years",{"count":40,"type":41},36,"ESTIMATED","INTERVENTIONAL",[44],"PHASE2","Most patients seeking abortion care or management of pregnancy loss in the second trimester will lactate, which can be physically and emotionally painful. The efficacy of a one-time dose of cabergoline has been previously demonstrated to prevent breast symptoms for these patients. This study seeks to determine if investigators can more precisely manage these patients with a reduced dose appropriate for the physiology of the second trimester, thereby reducing the medication cost and reducing or eliminating the uncomfortable medication side effects.",[47],"Lactation Suppressed","NOT_YET_RECRUITING","2025-12-05",{"date":51,"type":52},"2025-12-12","ACTUAL",{"date":54,"type":41},"2026-07",{"date":56,"type":41},"2027-07",{"name":5,"class":6}]